Kadimastem Ltd is a leading regenerative medicine company, public traded in the Tel Aviv stock exchange (TASE:KDST), with focus on the industrial development and commercialization of stem cell-based therapeutics. The company’s proprietary technologies and know-how enable the differentiation of stem cells into insulin-secreting beta cells as well as a range of neural cells (Oligodendrocytes, Astrocytes, neurons).  Based on its platform technologies, Kadimastem is advancing two therapeutic programs in diabetes mellitus and ALS, and, in addition, Kadimastem is partnering with pharmaceutical companies interested to screen (hit-lead, lead optimization) potential drug compounds on its stem-cell derived cells. Kadimastem employs 28 employees, among them 10 PhDs. Kadimastem develops its technologies in a 1700 m2 state-of-the-art facility equipped with two GMP cell culture production suites, at the Weizmann Science Park (Ness Ziona, Israel). We have fully equipped tissue cultures labs where we grow and differentiate hPSC into neural cell and beta cell derivatives. Kadimastem’s cell culture handling and drug screening process are fully automated and carried out by the EVO200 Tecan robot. Screening and analysis of the cultures are done by Image acquisition using the ArrayScan system (Cellomics). ScanArray data is collected and further processed using the JMP statistical software. Our QA are done by using FACS, real-time PCR, ELISA and IHC by florescent microscopy.